# Becton Dickinson & Co: Form 10-Q for the period ended Dec 31, 2009

- Company: [Becton Dickinson & Co](/companies/bdx.md) (CIK 10795)
- Form: 10-Q
- Filed: 2010-02-08
- Accepted by EDGAR: Feb 8, 2010, 17:17 ET
- Period: 2009-12-31
- Accession: 0000950123-10-009988
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/10795/000095012310009988/y81974e10vq.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/10795/000095012310009988/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2009-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2009-10-01 to 2009-12-31 | $1.92bn | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2009-10-01 to 2009-12-31 | $919.5m | us-gaap:CostOfGoodsAndServicesSold |
| Selling, general and administrative | 3 months, 2009-10-01 to 2009-12-31 | $450.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2009-10-01 to 2009-12-31 | $446.0m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2009-10-01 to 2009-12-31 | $13.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2009-10-01 to 2009-12-31 | $123.5m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2009-10-01 to 2009-12-31 | $316.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2009-10-01 to 2009-12-31 | $1.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2009-10-01 to 2009-12-31 | $1.33 | us-gaap:EarningsPerShareBasic |
| Operating cash flow | 3 months, 2009-10-01 to 2009-12-31 | $394.6m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 3 months, 2009-10-01 to 2009-12-31 | $111.6m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 3 months, 2009-10-01 to 2009-12-31 | $89.9m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 3 months, 2009-10-01 to 2009-12-31 | $191.1m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2009-12-31 | $1.18bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2009-12-31 | $4.06bn | us-gaap:AssetsCurrent |
| Total assets | at 2009-12-31 | $9.09bn | us-gaap:Assets |
| Current liabilities | at 2009-12-31 | $1.54bn | us-gaap:LiabilitiesCurrent |
| Current portion of debt | at 2009-12-31 | $205.4m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2009-12-31 | $5.26bn | us-gaap:StockholdersEquity |
| Shares outstanding | at 2009-12-31 | 235,699,337 shares | dei:EntityCommonStockSharesOutstanding |

## Management's discussion and analysis

As filed, 24,563 characters.

#### Company Overview

Becton, Dickinson and Company (“BD”) is a global medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. Our business consists of three worldwide business segments – BD Medical (“Medical”), BD Diagnostics (“Diagnostics”) and BD Biosciences (“Biosciences”). Our products are marketed in the United States and internationally through independent distribution channels and directly to end-users by BD and independent sales representatives.

#### Overview of Financial Results

BD reported first quarter revenues of $1.917 billion, representing an increase of 12% from the same period a year ago, and reflecting volume increases of approximately 9%, favorable foreign currency translation of approximately 3% and price decreases of less than 1%. The Medical and Diagnostics segments led revenue growth, which was aided by flu-related sales. Sales in the United States of safety-engineered devices in the first quarter of 2010 were $298 million, representing an 11% increase from the prior year’s period. International sales of safety-engineered devices of $156 million in the first quarter of 2010 grew 16% above such sales in the prior year’s period, after taking into account a 6% favorable impact due to foreign currency translation, net of hedge losses. Overall, first quarter international revenues were $1.044 billion, representing an increase of 13% above the prior year’s period, after taking into account an estimated 5% favorable impact due to foreign currency translation, net of hedge losses.

As further discussed in our 2009 Annual Report on Form 10-K, we face currency exposure each reporting period that arises from translating the results of our worldwide operations to the U.S. dollar at exchange rates that fluctuate from the beginning of such period. We purchase forward contracts to partially protect against adverse foreign exchange rate movements. Gains or losses on our derivative instruments are largely offset by the gains or losses on the underlying hedged transactions. We do not enter into derivative instruments for trading or speculative purposes. During the first quarter 2010, the U.S. dollar weakened against most foreign currencies, primarily the Euro, compared to rates during the first quarter of 2009. The resulting favorable impact of foreign currency translation on revenues in the first quarter 2010 was partially offset by hedge losses, recorded in Revenues, resulting from our hedging activities. For further discussion refer to Note 12 in the Notes to Condensed Consolidated Financial Statements.

#### Results of Operations

#### Revenues

Refer to Note 6 in the Notes to Condensed Consolidated Financial Statements for segment financial data.

#### Medical Segment

First quarter revenues of $1.019 billion represented an increase of $143 million, or 16%, over the prior year’s quarter, including an estimated $32 million, or 4%, favorable impact due to foreign currency translation, net of hedge losses. The revenue growth is attributable to strong sales of Medical Surgical Systems and Pharmaceutical Systems products, including about 7 percentage points of growth from flu-related products, as well as Diabetes Care products. Global sales of safety-engineered products were $228 million, a growth of 19% when compared to $193 million in the prior year’s quarter, and included a $4 million favorable impact due to foreign currency translation, net of hedge losses.

#### Diagnostics Segment

First quarter revenues of $595 million represented an increase of $55 million, or 10%, over the prior year’s quarter, including an estimated $11 million, or 2%, favorable impact due to foreign currency translation, net of hedge losses. Sales of safety-engineered devices and infectious disease testing systems, including about 2 percentage points of growth from flu-related products, contributed to revenue growth. Global sales of safety-engineered products of $226 million grew 7%, as compared with $210 million in the prior year’s quarter, and included a $4 million favorable impact due to foreign currency translation, net of hedge losses.

#### Biosciences Segment

First quarter revenues of $303 million were flat compared with the prior year’s quarter and included an estimated $2 million, or less than 1%, unfavorable impact due to foreign currency translation, inclusive of hedge losses. Demand for clinical and research instruments, as expected, continues to be impacted by capital funding constraints. Demand within the Discovery Labware unit was adversely impacted by a distributor’s inventory reduction as well as a delay in purchases from a large customer. Biosciences revenues reflected a larger portion of our hedge losses than the Medical and Diagnostics segments, as these losses are allocated to the segments based on their proportionate share of international sales of U.S.-produced products. For this reason, foreign currency translation had an unfavorable impact on Biosciences revenues for the quarter.

#### Segment Operating Income

#### Medical Segment

Segment operating income for the first quarter was $319 million, or 31.3% of Medical revenues, compared with $259 million, or 29.6% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than the first quarter of 2009 primarily due to unfavorable foreign currency translation, including hedge losses. Higher manufacturing start-up costs and higher pension costs allocated to the segment also contributed to the decrease from the prior period. These unfavorable impacts on gross profit margin were partially offset by decreases in certain raw material costs. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Medical revenues was lower in the first quarter of 2010 compared with the first quarter of 2009, as continued spending controls more than offset unfavorable foreign currency translation.

#### Diagnostics Segment

Segment operating income for the first quarter was $162 million, or 27.3% of Diagnostics revenues, compared with $155 million, or 28.6% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than in the first quarter of 2009 primarily due to unfavorable foreign currency translation, including hedge losses. Higher pension costs allocated to the segment also contributed to the decrease from the prior period. These unfavorable impacts on gross profit margin were partially offset by decreases in certain raw material costs. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Diagnostics revenues was lower in the first quarter of 2010 compared with the first quarter of 2009, as continued spending controls more than offset unfavorable foreign currency translation.

#### Biosciences Segment

Segment operating income for the first quarter was $85 million, or 28.2% of Biosciences revenues, compared with $100 million, or 33.0% of segment revenues, in the prior year’s quarter. Gross profit margin was lower in the current quarter than the first quarter of 2009 primarily due to the net unfavorable impact of foreign currency translation, including hedge losses. See further discussion on gross profit margin below. Selling and administrative expense as a percentage of Biosciences revenues for the first quarter of 2010 increased compared with the first quarter of 2009 primarily due to unfavorable foreign currency translation.

#### Gross Profit Margin

Gross profit margin was 52.0% for the first quarter, compared with 53.6% for the comparable prior year period. Gross profit margin in the first quarter of 2010 as compared with the prior year’s period reflected an estimated unfavorable impact of 190 basis points from both foreign currency translation and the hedging of certain foreign currencies, in particular the Euro, as previously discussed above under “Overview of Financial Results”. The operating performance impact on gross margin was favorable by 30 basis points as compared to prior year, and the result of decreases in certain raw material costs which were partially offset by higher manufacturing start-up costs and higher pension costs.

#### Selling and Administrative Expense

Selling and administrative expense was 23.5% of revenues for the first quarter, compared with 23.6% for the prior year’s period. Aggregate expenses for the current period reflect increases in core spending of $10 million, an estimated $19 million unfavorable impact of foreign currency translation, and an $11 million increase in the deferred compensation plan liability, as further discussed below. Aggregate expenses for the current period also reflect the recognition of a $5 million legal contingency. See Note 5 in the Notes to the Condensed Consolidated Financial Statements for further discussion.

#### Research and Development Expense

Research and development expense was $100 million for the first quarter, compared with the prior year’s amount of $97 million, an increase of 3% over the prior year’s period. Research and development expense was 5.2% of revenues in the first quarter, compared with 5.7% of revenues in the prior year’s period. The decrease in research and development expenditures as a percentage of revenues reflects the timing of expenses and is not indicative of the spending expected for the total year.

#### Non-Operating Expense and Income

Interest income was $9 million in the first quarter, compared with $2 million in the prior year’s period. The increase resulted from investment gains on assets related to our deferred compensation plan and higher investment levels, which was partially offset by the impact of lower interest rates during the period. The related increase in the deferred compensation plan liability was recorded as an increase in selling and administrative expenses. Interest expense was $13 million in the first quarter, compared with $8 million in the prior year’s period, which reflects higher levels of long-term fixed rate debt, partially offset by lower interest rates on floating rate debt. Other (expense) income was $(2) million in the first quarter, compared with $9 million in the prior year’s period, and includes an $8 million unfavorable change to net foreign exchange losses compared with the prior year’s period. The first quarter of 2009 also included $3 million of income relating to the completion of a collaborative research and development agreement for which there was no corresponding amount recognized in the current year’s period.

#### Income Taxes

The income tax rate was 28.1% for the first quarter, compared with the prior year’s rate of 26.6%. The increase is due to the impact of the reinstated research and experimentation tax credit in the prior year’s first quarter.

#### Diluted Earnings Per Share from Continuing Operations

Income from continuing operations and diluted earnings per share from continuing operations for the first quarter of 2010 were $316 million and $1.30, respectively. Income from continuing operations and diluted earnings per share from continuing operations for the prior year’s first quarter were $309 million and $1.25, respectively. The current quarter’s earnings reflect underlying performance as well as an estimated $0.09 overall unfavorable impact of foreign exchange fluctuations, including foreign exchange hedge losses, as discussed above.

#### Liquidity and Capital Resources

Cash generated from operations, along with available cash and cash equivalents, is expected to be sufficient to fund our normal operating needs, including capital expenditures, cash dividends and common stock repurchases in 2010. Net cash provided by continuing operating activities was $395 million during the first quarter of 2010, compared with $266 million in the same period in 2009. Net cash provided by continuing operations in the first quarters of the current and prior year was reduced by changes in the pension obligation, resulting primarily from discretionary cash contributions of approximately $175 million and $115 million, respectively. The change in working capital from the prior year’s period primarily reflects improved collections in the current period compared with the prior year’s period.

Net cash used for continuing investing activities for the first quarter of the current year was $142 million, compared with $129 million in the prior year period. Capital expenditures were $112 million in the first three months of 2010 and $95 million in the same period in 2009. The current year amount also reflects the payment of $275 million of net cash relating to the HandyLab acquisition.

Net cash used for continuing financing activities for the first quarter of the current year was $467 million, compared with $368 million in the prior year period. The change in short-term debt reflected the repayment of $200 million of 7.15% Notes, due October 1, 2009. For the first quarter of the current year, we repurchased $191 million of our common stock, compared with approximately $283 million of common stock repurchase in the prior year period. At December 31, 2009, authorization to repurchase an additional 15.1 million common shares remained in effect.

As of December 31, 2009, total debt of $1.7 billion represented 24.0% of total capital (shareholders’ equity, net non-current deferred income tax liabilities, and debt), versus 26.8% at September 30, 2009. Short-term debt decreased to 12% of total debt at the end of December 31, 2009, from 21% at September 30, 2009.

We have in place a commercial paper borrowing program that is available to meet our short-term financing needs, including working capital requirements. Borrowings outstanding under this program were $200 million at December 31, 2009. We have available a $1 billion syndicated credit facility with an expiration date in December 2012. This credit facility, under which there were no borrowings outstanding at December 31, 2009, provides backup support for our commercial paper program and can also be used for other general corporate purposes. This credit facility includes a single financial covenant that requires BD to maintain an interest expense coverage ratio (ratio of earnings before income taxes, depreciation and amortization to interest expense) of not less than 5-to-1 for the most recent four consecutive fiscal quarters. On the last eight measurement dates, this ratio has ranged from 27-to-1 to 34-to-1. In addition, we have informal lines of credit outside the United States.

#### Greek Government Receivables

Accounts receivable balances include sales to government-owned or supported healthcare facilities in Greece. These sales are subject to significant payment delays due to government funding and reimbursement practices. We believe that this is an industry-wide issue for suppliers to these facilities. The outstanding balances, net of reserves related to such sales, were approximately $41 million and $45 million at December 31, 2009 and September 30, 2009, respectively. If significant changes occur in the availability of government funding, we may not be able to collect on amounts due from these customers. We do not expect this concentration of credit risk to have a material adverse impact on our financial position or liquidity.

#### Cautionary Statement Regarding Forward-Looking Statements

BD and its representatives may from time-to-time make certain forward-looking statements in publicly released materials, both written and oral, including statements contained in filings with the Securities and Exchange Commission, press releases and our reports to shareholders. Forward-looking statements may be identified by the use of words such as “plan,” “expect,” “believe,” “intend,” “will,” “anticipate,” “estimate” and other words of similar meaning in conjunction with, among other things, discussions of future operations and financial performance, as well as our strategy for growth, product development, regulatory approvals, market position and expenditures. All statements that address operating performance or events or developments that we expect or anticipate will occur in the future — including statements relating to volume growth, sales and earnings per share growth, cash flows or uses, and statements expressing views about future operating results — are forward-looking statements.

Forward-looking statements are based on current expectations of future events. The forward-looking statements are, and will be, based on management’s then-current views and assumptions regarding future events and operating performance, and speak only as of their dates. Investors should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections. Investors are therefore cautioned not to place undue reliance on any forward-looking statements. Furthermore, we undertake no obligation to update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events and developments or otherwise, except as required by applicable law or regulations.

The following are some important factors that could cause our actual results to differ from our expectations in any forward-looking statements.

- The current economic downturn and continued instability in the global financial markets and the potential adverse effect on liquidity and capital resources for BD or its customers and suppliers, the cost of operating our business, the demand for our products and services, or the ability to produce our products. This includes the impact on developing countries and their demand for our products.
- The effects, if any, of healthcare reform in the U.S., including various proposals that, if enacted, would impose an excise tax on medical device manufacturers such as BD. Other legislative or administrative reforms in the U.S. or abroad could also reduce reimbursement rates, result in increased pricing pressures or otherwise adversely affect BD’s business.
- Changes in domestic and foreign healthcare industry practices that result in increased pricing pressures, including the continued consolidation among healthcare providers and trends toward managed care and healthcare cost containment.
- Regional, national and foreign economic factors, including inflation, deflation, and fluctuations in interest rates and, in particular, foreign currency exchange rates, and the potential effect of such fluctuations on revenues, expenses and resulting margins, and credit ratings, as well as competition in certain markets.
- The effects of natural disasters, including pandemic diseases, earthquakes, fire, or the effects of climate change on our ability to manufacture our products, particularly where production of a product line is concentrated in one or more plants, or on our ability to source components from suppliers that are needed for such manufacturing.
- Fluctuations in the cost and availability of oil-based resins and other raw materials, as well as certain sub-assemblies and finished goods, and the ability to maintain favorable supplier arrangements and relationships (particularly with respect to sole-source suppliers) and the potential adverse effects of any disruption in the availability of such items.
- We operate in a highly competitive environment. New product introductions by our current or future competitors (for example, new forms of drug delivery) could adversely affect our ability to compete in the global market. Patents attained by competitors, particularly as patents on our products expire, may also adversely impact our competitive position. Certain competitors have established manufacturing sites or have contracted with suppliers in low-cost manufacturing locations as a means to lower their costs. New entrants may also appear.
- Difficulties inherent in product development, including the potential inability to successfully continue technological innovation, complete clinical trials, obtain regulatory approvals in the United States and abroad, obtain coverage and adequate reimbursement for new products, or gain and maintain market approval of products, as well as the possibility of encountering infringement claims by competitors with respect to patent or other intellectual property rights, all of which can preclude or delay commercialization of a product.

26

- We sell certain products to pharmaceutical companies that are used to manufacture, or are sold with, products by such companies. As a result, fluctuations in demand for the products of these pharmaceutical companies could adversely affect our operating results.
- The effects, if any, of governmental and media activities regarding the business practices of group purchasing organizations, which negotiate product prices on behalf of their member hospitals with BD and other suppliers.
- Our ability to obtain the anticipated benefits of restructuring programs, if any, that we may undertake.
- Our ability to implement the upgrade of our enterprise resource planning system. Any delays or deficiencies in the design and implementation of our upgrade could adversely affect our business.
- Adoption of, or changes in, government laws and regulations affecting domestic and foreign operations, including those relating to trade, monetary and fiscal policies, taxation (including tax reforms that could adversely impact multinational corporations), environmental matters, sales practices, price controls, licensing and regulatory approval of new products, regulatory requirements for products in the postmarketing phase, or changes in enforcement practices with respect to any such laws and regulations. In particular, environmental laws, particularly with respect to the emission of greenhouse gases, are becoming more stringent throughout the world, which may increase our costs of operations or necessitate changes in our manufacturing plants or processes.
- Fluctuations in U.S. and international governmental funding and policies for life sciences research.
- Pending and potential litigation or other proceedings adverse to BD, including antitrust claims, product liability claims, patent infringement claims, and the availability or collectibility of insurance relating to any such claims.
- The effects of adverse media exposure or other publicity regarding BD’s business or operations.
- Our ability to achieve the projected level or mix of product sales. Our earnings forecasts are generated based on such projected volumes and sales of many product types, some of which are more profitable than others.
- The effect of market fluctuations on the value of assets in BD’s pension plans and the possibility that BD may need to make additional contributions to the plans as a result of any decline in the value of such assets.
- Product efficacy or safety concerns resulting in product recalls, regulatory action on the part of the U.S. Food and Drug Administration (or foreign counterparts) or declining sales.

27

- Political conditions in international markets, including civil unrest, terrorist activity, governmental changes, restrictions on the ability to transfer capital across borders and expropriation of assets by a government.
- Our ability to penetrate developing and emerging markets, which also depends on economic and political conditions, and how well we are able to acquire or form strategic business alliances with local companies and make necessary infrastructure enhancements to production facilities, distribution networks, sales equipment and technology.
- The impact of business combinations, including any volatility in earnings relating to acquired in-process research and development assets, and our ability to successfully integrate any business we may acquire.
- Issuance of new or revised accounting standards by the Financial Accounting Standards Board or the Securities and Exchange Commission.

The foregoing list sets forth many, but not all, of the factors that could impact our ability to achieve results described in any forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider this list to be a complete statement of all potential risks and uncertainties.

## Controls and procedures

As filed, 3,022 characters.

There were no matters submitted to a vote of security holders during the fiscal quarter ended December 31, 2009.

Our Annual Meeting of Shareholders was held on February 2, 2010, at which the following matters were voted upon:

i.) A management proposal for the election of eight directors for the terms indicated below was voted upon as follows:

| Nominee | Term | Votes For Votes | Withheld |
| --- | --- | ---: | ---: |
| Henry P. Becton, Jr. | 1 Year | 159,137,090 | 12,848,272 |
| Edward F. DeGraan | 1 Year | 165,600,066 | 6,385,296 |
| Claire M. Fraser-Liggett | 1 Year | 162,624,080 | 9,361,282 |
| Edward J. Ludwig | 1 Year | 163,494,713 | 8,490,649 |
| Adel A.F. Mahmoud | 1 Year | 162,577,411 | 9,407,951 |
| James F. Orr | 1 Year | 166,243,762 | 5,741,600 |
| Willard J. Overlock, Jr. | 1 Year | 161,330,616 | 10,654,746 |
| Bertram L. Scott | 1 Year | 161,474,395 | 10,510,967 |

|  |  |
| --- | --- |
|  | The directors whose term of office as a director continued after the meeting are: Basil L. Anderson, Marshall O. Larsen, Gary A. Mecklenburg, Cathy E. Minehan and Alfred Sommer. |
| ii.) | A management proposal to ratify the selection of Ernst & Young, LLP as independent registered public accounting firm for the fiscal year ending September 30, 2010 was voted upon. 194,029,524 shares were voted for the proposal, 1,915,229 shares were voted against, and 274,053 shares abstained. |
| iii.) | A management proposal to amend BD’s By-Laws to permit holders of at least 25% of the voting power of the outstanding capital stock to call a special meeting of shareholders was voted upon. 169,633,759 shares were voted for the proposal, 1,987,487 shares were voted against, 363,991 shares abstained, and there were 24,233,569 broker non-votes. |
| iv.) | A management proposal to amend the 2004 Employee and Director Equity-Based Compensation Plan was voted upon. 154,575,403 shares were voted for the proposal, 16,914,562 shares were voted against, 495,272 shares abstained, and there were 24,233,569 broker non-votes. |
| v.) | A management proposal requesting approval of material terms of performance goals under the 2004 Employee and Director Equity-Based Compensation Plan. 167,608,863 shares were voted for the proposal, 3,806,596 shares were voted against, 569,778 shares abstained, and there were 24,233,569 broker non-votes. |
| vi.) | A shareholder proposal requesting that the Board of Directors take the necessary steps to provide for majority voting in the election of directors was voted upon. 84,399,479 shares were voted for the proposal, 85,629,269 shares were voted against, 1,956,614 shares abstained, and there were 24,233,444 broker non-votes. |
| vii.) | A shareholder proposal requesting that the Board of Directors take the necessary steps to provide for cumulative voting in the election of directors was voted upon. 57,636,133 shares were voted for the proposal, 112,730,964 shares |

32 were voted against, 1,618,265 shares abstained, and there were 24,233,444 broker non-votes.

## Risk factors

As filed, 147 characters.

There have been no material changes from the risk factors disclosed in Part 1, Item 1A, of our Annual Report on Form 10-K for the 2009 fiscal year.

Filed Feb 8, 2010.
Source: SEC EDGAR, the filing index for accession 0000950123-10-009988. Last ingested by Listed: Nov 11, 2026, 03:43 ET. No prices; not investment advice.
